Company Overview and News

0
Nestle won't dent a2 Milk's China prospects - Harbour Asset Management

2018-05-13 nzherald.co.nz
Nestle's incursion into the A1-free beta protein infant formula market in China is unlikely to damage NZX-listed a2 Milk Co's prospects there, Harbour Asset Management senior analyst Oyvinn Rimer said.
LGO

7
Brian Gaynor: Week brings bad news for the NZX

2018-04-13 nzherald.co.nz
It hasn't been a great week for the NZX, with the delisting of Trilogy International, Happy Valley Milk's decision to list on the ASX and Icebreaker's confirmed purchase price by US apparel giant VF Corp when an NZX listing was a potential alternative.
ASXFF NZSTY ANZLY AIR ASXFY NZSTF ANZFF ANZFY AIZ LGO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:LGO / LONGREACH OIL LIMITED on message board site Silicon Investor.

ALGORE THE POWERFUL Calgon Carbon (CCC)
LGOV - Largo Vista Group, Ltd. Luna Technolgoies Intl
LGOV - Largo Vista Group, Ltd. - 2005 u0026 Beyond........ LGOV: For the Serious Investor
Largo Vista -Crown Jewel of China 1998 and Beyond! LGOV AlgoRx (AGRX)
Nasdaq Algorithm Explained ALG - Algoma Steel